| Literature DB >> 29426276 |
Ryosuke Matsuno1, Andrew J Gifford2,3, Junming Fang4, Mikako Warren1, Robyn E Lukeis5, Toby Trahair6, Tohru Sugimoto7, Araz Marachelian8, Shahab Asgharzadeh1,8, John M Maris9, Naohiko Ikegaki10, Hiroyuki Shimada1.
Abstract
Background Although MYCN (aka N-myc) amplification is reported in ∼20% of neuroblastomas, MYC (aka C-myc) amplification appears to be a rare event in this disease. As of today, only 2 MYC-amplified neuroblastomas have been briefly mentioned in the literature. Methods We studied here the clinicopathological features of 3 MYC-amplified neuroblastomas. Results All 3 patients (2 females and 1 male) had stage 4 disease. One female is currently alive and well 52 months after the diagnosis, while the other female and male patients died of disease 24 and 20 months after the diagnosis, respectively. Further analysis on 2 tumors revealed unfavorable histology with MYC protein overexpression but with neither MYCN amplification nor MYCN protein overexpression. Both of these tumors exhibited "large cell neuroblastoma" histology with enlarged, uniquely open nuclei and nucleolar hypertrophy, along with "aberrant" desmin expression. Conclusions MYC-amplified neuroblastomas are extremely rare and seem to present with distinct clinicopathological features.Entities:
Keywords: MYC amplification; MYC protein overexpression; large cell; neuroblastoma; no MYCN amplification; unfavorable histology
Mesh:
Substances:
Year: 2018 PMID: 29426276 DOI: 10.1177/1093526617749670
Source DB: PubMed Journal: Pediatr Dev Pathol ISSN: 1093-5266